Health Economics›Follicular lymphoma›Advanced disease first-line therapy non-randomized or retrospective data

Advanced disease first-line therapy non-randomized or retrospective data

Follicular lymphoma · 9 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 2 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Bendamustine and Ofatumumab Variant #01	—	R 1 183 782	28d	—	—	—	—	—
O-CHOP Variant #01	—	R 666 903	21d	—	—	—	—	—
Fludarabine and Rituximab (FR) Variant #06	—	R 117 749	28d	—	—	—	—	—
Bortezomib and Rituximab (VR) Variant #06	—	R 64 235	35d	~12.8 mo	—	~12	~R 770 814 PFS proxy · indirect	1
R-FCM Variant #04	—	R 46 093	42d	—	—	—	—	—
R-CMD Variant #01	—	R 31 214	21d	—	—	—	—	—
Ibritumomab tiuxetan protocol Variant #18	—	R 27 524	8d	~36.5 mo	—	~139	~R 3 825 804 PFS proxy · indirect	1
VR-CHOP Variant #01	—	R 14 802	21d	—	—	—	—	—
PCR N/A - secondary systemic drug Partial	—	R 172	28d	—	—	—	—	—

9 of 9 regimens shown